Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.60M | 51.20M | -12.00M | 68.00M | -31.30M |
| Total Depreciation and Amortization | 23.50M | 23.40M | 23.50M | 25.40M | 26.00M |
| Total Amortization of Deferred Charges | 2.60M | 2.50M | 2.40M | 2.30M | 2.20M |
| Total Other Non-Cash Items | 24.20M | 2.00M | -3.20M | 11.80M | 8.50M |
| Change in Net Operating Assets | 82.00M | -81.40M | 95.70M | -118.70M | -85.30M |
| Cash from Operations | 77.70M | -2.30M | 106.40M | -11.20M | -79.90M |
| Capital Expenditure | -3.90M | -3.40M | -2.90M | -3.60M | -1.70M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 100.00K | 38.10M | 300.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | 0.00 | 0.00 | 20.00M | 25.00M | 30.00M |
| Cash from Investing | -3.90M | -3.40M | 17.20M | 59.50M | 28.60M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -105.60M | -6.90M | -- | -- | 0.00 |
| Issuance of Common Stock | 1.20M | 200.00K | 700.00K | 100.00K | 800.00K |
| Repurchase of Common Stock | -9.50M | -9.20M | -7.10M | -500.00K | -300.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | -113.90M | -15.90M | -6.40M | -400.00K | 500.00K |
| Foreign Exchange rate Adjustments | 0.00 | -200.00K | 1.00M | -700.00K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.10M | -21.80M | 118.20M | 47.20M | -50.80M |